Literature DB >> 9652417

Limited variability of glycoprotein gene sequences and neutralizing targets in herpes simplex virus type 2 isolates and stability on passage in cell culture.

S S Terhune1, K T Coleman, R Sekulovich, R L Burke, P G Spear.   

Abstract

Nucleotide sequence analyses of polymerase chain reaction-amplified genes were performed to determine whether adaptation of herpes simplex virus type 2 to replication in cultured cells or in internal organs during neonatal disseminated disease results in selection of variants with altered forms of three glycoproteins (gB, gC, or gD) that influence virus entry into cells. No variations in sequence were noted as a consequence of in vitro passage or replication in different organs. Five viruses from different subjects differed with respect to gB, gC, and gD gene sequences, expressing four distinct forms of gB, three of gC, and two of gD. These differences did not confer resistance to neutralization by guinea pig or human antisera from subjects immunized with recombinant gB or gD vaccines and may not be consequential for vaccine development.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652417     DOI: 10.1086/515590

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Conservation of type-specific B-cell epitopes of glycoprotein G in clinical herpes simplex virus type 2 isolates.

Authors:  J A Liljeqvist; B Svennerholm; T Bergström
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

2.  Variability of the glycoprotein G gene in clinical isolates of herpes simplex virus type 1.

Authors:  E Rekabdar; P Tunbäck; J A Liljeqvist; T Bergström
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry.

Authors:  B C Herold; I Scordi-Bello; N Cheshenko; D Marcellino; M Dzuzelewski; F Francois; R Morin; V Mas Casullo; R A Anderson; C Chany; D P Waller; L J D Zaneveld; M E Klotman
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Herpes simplex virus type 2 glycoprotein G-negative clinical isolates are generated by single frameshift mutations.

Authors:  J A Liljeqvist; B Svennerholm; T Bergström
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Dichotomy of glycoprotein g gene in herpes simplex virus type 1 isolates.

Authors:  Elham Rekabdar; Petra Tunbäck; Jan-Ake Liljeqvist; Magnus Lindh; Tomas Bergström
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

6.  Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections.

Authors:  Rebecca Pellett Madan; Pedro M M Mesquita; Natalia Cheshenko; Bingwen Jing; Vikas Shende; Esmeralda Guzman; Taylor Heald; Marla J Keller; Steven L Regen; Robin J Shattock; Betsy C Herold
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

7.  Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection.

Authors:  William J Muller; Lichun Dong; Adrian Vilalta; Benjamin Byrd; Kai M Wilhelm; Christopher L McClurkan; Michal Margalith; Chao Liu; David Kaslow; John Sidney; Alessandro Sette; David M Koelle
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

8.  Divergence and recombination of clinical herpes simplex virus type 2 isolates.

Authors:  Peter Norberg; Mabula J Kasubi; Lars Haarr; Tomas Bergström; Jan-Ake Liljeqvist
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

9.  NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2.

Authors:  Sara Sinha; Natalia Cheshenko; Robert I Lehrer; Betsy C Herold
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.

Authors:  Natalia Cheshenko; Marla J Keller; Veronica MasCasullo; Gary A Jarvis; Hui Cheng; Minnie John; Jin-Hua Li; Kathleen Hogarty; Robert A Anderson; Donald P Waller; Lourens J D Zaneveld; Albert T Profy; Mary E Klotman; Betsy C Herold
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.